Biosimilars in India; Current Status and Future Perspectives

Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop the similar biologics. Biosimilar or similar biologic used has increased in the recent year following the approval of the first biosimilar in ear...

Descripción completa

Detalles Bibliográficos
Autores principales: Meher, Bikash R., Balan, Sakthi, Mohanty, Rashmi R., Jena, Monalisa, Das, Smita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394151/
https://www.ncbi.nlm.nih.gov/pubmed/30906134
http://dx.doi.org/10.4103/jpbs.JPBS_167_18
_version_ 1783398835105562624
author Meher, Bikash R.
Balan, Sakthi
Mohanty, Rashmi R.
Jena, Monalisa
Das, Smita
author_facet Meher, Bikash R.
Balan, Sakthi
Mohanty, Rashmi R.
Jena, Monalisa
Das, Smita
author_sort Meher, Bikash R.
collection PubMed
description Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop the similar biologics. Biosimilar or similar biologic used has increased in the recent year following the approval of the first biosimilar in early 2000. India is one of the leading manufacturers of similar biologics. India has developed a new guideline in 2012 for the pre- and post-marketing approval of similar biologics.
format Online
Article
Text
id pubmed-6394151
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-63941512019-03-22 Biosimilars in India; Current Status and Future Perspectives Meher, Bikash R. Balan, Sakthi Mohanty, Rashmi R. Jena, Monalisa Das, Smita J Pharm Bioallied Sci Review Article Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop the similar biologics. Biosimilar or similar biologic used has increased in the recent year following the approval of the first biosimilar in early 2000. India is one of the leading manufacturers of similar biologics. India has developed a new guideline in 2012 for the pre- and post-marketing approval of similar biologics. Medknow Publications & Media Pvt Ltd 2019 /pmc/articles/PMC6394151/ /pubmed/30906134 http://dx.doi.org/10.4103/jpbs.JPBS_167_18 Text en Copyright: © 2019 Journal of Pharmacy and Bioallied Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Meher, Bikash R.
Balan, Sakthi
Mohanty, Rashmi R.
Jena, Monalisa
Das, Smita
Biosimilars in India; Current Status and Future Perspectives
title Biosimilars in India; Current Status and Future Perspectives
title_full Biosimilars in India; Current Status and Future Perspectives
title_fullStr Biosimilars in India; Current Status and Future Perspectives
title_full_unstemmed Biosimilars in India; Current Status and Future Perspectives
title_short Biosimilars in India; Current Status and Future Perspectives
title_sort biosimilars in india; current status and future perspectives
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394151/
https://www.ncbi.nlm.nih.gov/pubmed/30906134
http://dx.doi.org/10.4103/jpbs.JPBS_167_18
work_keys_str_mv AT meherbikashr biosimilarsinindiacurrentstatusandfutureperspectives
AT balansakthi biosimilarsinindiacurrentstatusandfutureperspectives
AT mohantyrashmir biosimilarsinindiacurrentstatusandfutureperspectives
AT jenamonalisa biosimilarsinindiacurrentstatusandfutureperspectives
AT dassmita biosimilarsinindiacurrentstatusandfutureperspectives

Ejemplares similares